TradeOrgs
  • 🇮🇳 India
  • 🇺🇸 US
  • Screener
  • Backtest
  • Watchlist
  • Signals
  • Portfolio
  • Insights
  • Connect
Sign in
RELIANCE₹1,377.50▲ 14.60%TCS₹2,376.20▼ 3.44%HDFCBANK₹846.00▲ 18.82%ICICIBANK₹1,640.00▲ 18.75%INFY₹1,098.00▼ 2.89%HINDUNILVR₹2,052.50▲ 10.75%ITC₹299.10▲ 14.69%SBIN₹1,165.10▲ 19.66%BHARTIARTL₹2,161.70▲ 15.28%KOTAKBANK₹515.80▲ 16.62%LT₹4,209.10▲ 14.94%AXISBANK₹1,446.00▲ 16.99%ASIANPAINT₹2,608.30▲ 11.91%MARUTI₹14,011.00▲ 22.10%AAPL$342.56▲ 0.90%MSFT$484.52▼ 8.90%GOOGL$265.29▼ 22.04%AMZN$246.82▼ 6.02%NVDA$125.53▼ 42.01%META$560.84▼ 19.22%TSLA$345.82▼ 7.46%BRK-B$570.00▲ 5.59%JPM$310.53▼ 7.38%V$401.87▼ 1.16%
RELIANCE₹1,377.50▲ 14.60%TCS₹2,376.20▼ 3.44%HDFCBANK₹846.00▲ 18.82%ICICIBANK₹1,640.00▲ 18.75%INFY₹1,098.00▼ 2.89%HINDUNILVR₹2,052.50▲ 10.75%ITC₹299.10▲ 14.69%SBIN₹1,165.10▲ 19.66%BHARTIARTL₹2,161.70▲ 15.28%KOTAKBANK₹515.80▲ 16.62%LT₹4,209.10▲ 14.94%AXISBANK₹1,446.00▲ 16.99%ASIANPAINT₹2,608.30▲ 11.91%MARUTI₹14,011.00▲ 22.10%AAPL$342.56▲ 0.90%MSFT$484.52▼ 8.90%GOOGL$265.29▼ 22.04%AMZN$246.82▼ 6.02%NVDA$125.53▼ 42.01%META$560.84▼ 19.22%TSLA$345.82▼ 7.46%BRK-B$570.00▲ 5.59%JPM$310.53▼ 7.38%V$401.87▼ 1.16%

TradeOrgs shows market information and analyzes your own trading history. It does not place trades and is not investment advice.

Prices and listings are for information only. We are read-only against your broker account.

Technical signals (RSI, MACD, etc.) are educational readouts of public indicators — not recommendations.

Privacy Policy·© 2026 TradeOrgs

← US stocks

🇺🇸AEON

AEON Biopharma, Inc. Class A Common Stock

NYSE
$0.12
▼ $0.11 (-47.0%)
Live· just now
delayed feed · not for order timing

Price history · 20-day (cyan) / 50-day (purple) avg

as of 20 Nov 2026
H $0.90L $0.11-87.5%
$0.9$0.74$0.58$0.43$0.27$0.11$0.11
RSI (14)
Intraday · 15-minStrong sell-55RSI 42DowntrendMACD Bearishfor day-trading context — not advice

Technical signal

Strong sell-45
RSI (14)26
oversold 30overbought 70
Trend
Downtrend
MACD
Bearish
Bollinger
Within bands
vs 20-day
below
vs 50-day
below
vs 200-day
below
Support
$0.11
Resistance
$0.31
  • Price is below its 50-day average (medium-term weakness).
  • RSI is 26 — oversold, a level some traders read as a potential entry zone.

Signal backtest · 2026-02-13 → 2026-11-17

Strategy return
-42.2%
Buy & hold
-89.0%
Trades
6
Win rate
0%

$100,000.00 invested would be worth $57,801.39 (-42.2%) · Full backtester →

Hypothetical: go long when the signal turns Buy, exit when it turns Sell. Past indicator behavior is not a prediction — educational only, not advice.

About AEON Biopharma, Inc.· Biotechnology

source: yahoo

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.

Sector
Healthcare
Industry
Biotechnology
Employees
8
Headquarters
Irvine, United States
www.aeonbiopharma.com ↗

Fundamentals

No fundamental data is currently available for this listing from our data providers.

Recent news

News sentiment:▲ Positive1↑ · 0↓ · 7–
  • AEON Biopharma Reports Third Quarter 2026 Financial Results and Provides Corporate Update— Neutral
    GlobeNewswire · 16 Nov 2026
  • AEON Biopharma Submits IND for Comparative Pharmacodynamic Study of ABP-450— Neutral
    GlobeNewswire · 09 Nov 2026
  • AEON Biopharma Reports Inducement Grant Under NYSE American LLC Company Guide Section 711— Neutral
    GlobeNewswire · 09 Oct 2026
  • AEON: Initiating Coverage – Imitation is a Sincere Form of Flattery: Seeking a Botox Biosimilar

Educational technical indicators — not investment advice. TradeOrgs does not place trades.

— Neutral
Zacks Small Cap Research · 05 Oct 2026
  • AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450— Neutral
    GlobeNewswire · 30 Sept 2026
  • Top Premarket Gainers— Neutral
    MT Newswires · 10 Sept 2026
  • Sentiment is a keyword-based read of the headline — a rough signal, not advice.